Boston Scientific Corporation (BSX) vs Regeneron Pharmaceuticals, Inc. (REGN)
A side-by-side comparison of Boston Scientific Corporation and Regeneron Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of September 13, 2026. Differences are shown without an overall score or investment verdict.
BSX
Boston Scientific Corporation
$43.91HealthcareDelayed quote: Sep 15, 2026, 10:35 AM EDT
REGN
Regeneron Pharmaceuticals, Inc.
$776.60HealthcareDelayed quote: Sep 15, 2026, 10:30 AM EDT
Total return — BSX vs REGN
growth of $100 · dividends reinvested · last 10yBSX +76.1% (+5.8%/yr)REGN +97.4% (+7.0%/yr)REGN compounded faster over this window
BSX REGN
BSX vs REGN: by the numbers
- •REGN is the larger company ($80.01B vs $65.27B market cap).
- •BSX trades at the lower trailing earnings multiple (17.85 vs 19.21 P/E), one valuation lens rather than an overall verdict.
- •REGN converts more revenue to profit (27.86% vs 17.47% net margin).
- •BSX grew revenue faster over the past five years (13.40% vs 4.64% CAGR).
- •REGN pays a dividend (0.47% yield), while BSX has no payments in the available dividend history.
Metrics side by side
Valuation
| Metric | BSX | REGN |
|---|---|---|
| P/E ratio | 17.85 | 19.21 |
| Forward P/E | 13.35 | 14.25 |
| P/S ratio | 3.11 | 5.15 |
| P/B ratio | 2.62 | 2.52 |
| EV / EBITDA | 13.34 | 17.68 |
| FCF yield | 5.55% | 4.40% |
Profitability
| Metric | BSX | REGN |
|---|---|---|
| Gross margin | 71.16% | 84.86% |
| Operating margin | 21.46% | 25.56% |
| Net margin | 17.47% | 27.86% |
| ROE | 14.71% | 13.65% |
| ROIC | 10.57% | 9.19% |
Dividends
| Metric | BSX | REGN |
|---|---|---|
| Dividend yield | N/A | 0.47% |
| Payout ratio | N/A | 9.15% |
Growth (annualized)
| Metric | BSX | REGN |
|---|---|---|
| Revenue CAGR (5Y) | 13.40% | 4.64% |
| EPS CAGR (5Y) | N/A | 5.70% |
| FCF CAGR (5Y) | 15.64% | 15.77% |
| Total return CAGR (5Y) | -0.67% | 3.93% |
Frequently asked
- Which has the lower trailing P/E, BSX or REGN?
- BSX has the lower trailing P/E: BSX trades at 17.85 and REGN at 19.21. P/E is one valuation measure and does not by itself establish which business is cheaper.
- Which has grown faster, BSX or REGN?
- Over the past five years, BSX grew revenue faster — BSX at a 13.40% CAGR versus REGN at 4.64%.
- Does BSX or REGN pay a bigger dividend?
- REGN pays a dividend (0.47% yield), while BSX has no payments in the available dividend history.
- Is BSX or REGN more profitable?
- REGN runs the higher net margin — BSX at 17.47% versus REGN at 27.86%.
- How have BSX and REGN total returns compared?
- Over the past 10 years, BSX delivered 6.22% and REGN delivered 7.45% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Boston Scientific P/E ratioRegeneron Pharmaceuticals P/E ratioRegeneron Pharmaceuticals dividend yieldBoston Scientific ROERegeneron Pharmaceuticals ROEBoston Scientific operating marginRegeneron Pharmaceuticals operating marginBoston Scientific revenue growthRegeneron Pharmaceuticals revenue growthBoston Scientific free cash flowRegeneron Pharmaceuticals free cash flow
Boston Scientific & Regeneron Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified September 13, 2026.